Regentis Biomaterials Ltd
Graf
Godt at vide: Investering i aktier giver typisk et positivt afkast på lang sigt, men indebærer også risiko. Du kan miste dele af eller hele din investering. Tidligere data for denne aktie er ikke en pålidelig indikator for fremtidige afkast. Data fra eksterne udbydere er ikke blevet ændret af Saxo. Se fuld ansvarsfraskrivelse for data.
Om Regentis Biomaterials Ltd
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
/ 